+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years - 80Years
All Genders
ID07227103

Evaluating NRX-101 with Robotic Transcranial Magnetic Stimulation for Adults with Treatment Resistant Depression A Randomized, Double-Blind Controlled Trial

Led by NeuroRx, Inc. · Updated on 2026-10-21

240

Participants Needed

3

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating treatments for treatment-resistant major depressive disorder MDD, a common and disabling condition worldwide. This trial evaluates whether a single day of Rapid Robotically-controlled Transcranial Magnetic Stimulation RRTMS combined with the investigational drug NRX-101 a combination of D-cycloserine and lurasidone can improve clinical response and remission compared to sham TMS or placebo. The study seeks to develop a rapid and durable treatment alternative for patients who do not respond well to existing therapies, especially those with demanding jobs such as military personnel and first responders. Participants will receive one of three treatments on the day of intervention RRTMS with NRX-101, RRTMS with placebo, or sham TMS with NRX-101. The RRTMS procedure is performed with a neuronavigated robotic system delivering theta burst pulses. NRX-101 consists of oral doses of D-cycloserine and lurasidone. Sham TMS uses a device configured not to deliver effective brain stimulation. This randomized, double-blind trial will enroll 240 adults and compare outcomes at six weeks post-treatment. Throughout the study, participants will be assessed for depression severity and suicidality using standardized scales such as the Montgomery-sberg Depression Rating Scale MADRS and the Columbia Suicide Severity Rating Scale CGI-SS. Additional measures include response and remission rates and depression symptom questionnaires. The trial includes monitoring for adherence, adverse events, and safety. Participation lasts at least six weeks, with evaluations to determine the treatments impact on depression and suicidality.

CONDITIONS

Brief Title

A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial

Research Team

M

Martin Goodwin, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here